Global Pharmaceutical CDMO Market

Global pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) market by CMO type (active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging), by CRO research phase (pre-clinical, phase I, phase II, phase III, phase IV), by region (North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America), outlook & forecast, 2022-2028

Report Code: GP03621R Industry: Region:
Description

According to market research study published by Gen Consulting Company, the market size of the global pharmaceutical CDMO sector is expected to rise by USD 78.0 billion with a CAGR of 6.2% by the end of 2028.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global pharmaceutical CDMO market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the pharmaceutical CDMO industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the CMO type, CRO research phase, and region. The global market for pharmaceutical CDMO can be segmented by CMO type: active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging. The active pharmaceutical ingredient (API) manufacturing segment is estimated to account for the largest share of the global pharmaceutical CDMO market. Pharmaceutical CDMO market is further segmented by CRO research phase: pre-clinical, phase I, phase II, phase III, phase IV. The phase III segment held the largest revenue share in 2021. Based on region, the pharmaceutical CDMO market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. Globally, North America made up the largest share of the pharmaceutical CDMO market.

The finished dosage formulation (FDF) development and manufacturing market is further segmented into solid dose formulation, liquid dose formulation, injectable dose formulation. The solid dose formulation segment held the largest share of the global pharmaceutical CDMO market in 2021 and is anticipated to hold its share during the forecast period. Furthermore, the API manufacturing market has been categorized into small molecule, large molecule, high potency API (HPAPI). In 2021, the small molecule segment made up the largest share of revenue generated by the pharmaceutical CDMO market.

Market Segmentation
By CMO type: active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging
By CRO research phase: pre-clinical, phase I, phase II, phase III, phase IV
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report has also analysed the competitive landscape of the global pharmaceutical CDMO market with some of the key players being Baxter Pharmaceutical Solutions LLC, Boehringer Ingelheim GmbH, Catalent Inc., CMIC Holdings Co., Ltd., Covance Inc., Hangzhou Tigermed Consulting Co., Ltd., ICON plc, IQVIA Holdings Inc., Jubilant Life Sciences Ltd., Lonza Group AG, Novotech Pty Ltd., PAREXEL International Corporation, Patheon Inc., Pfizer CentreSource, PPD, Inc., Recipharm AB, Samsungbioepis Co,. Ltd., Syneos Health Inc., WuXi AppTec Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global pharmaceutical CDMO market.
– To classify and forecast the global pharmaceutical CDMO market based on CMO type, CRO research phase, region.
– To identify drivers and challenges for the global pharmaceutical CDMO market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global pharmaceutical CDMO market.
– To identify and analyze the profile of leading players operating in the global pharmaceutical CDMO market.

Why Choose This Report
– Gain a reliable outlook of the global pharmaceutical CDMO market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.

Global Pharmaceutical CDMO Market

Interested in this report? Get your FREE sample now!

$2,950.00

Code: GP03621R Industry: Region:

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
Global Pharmaceutical CDMO Market

Please fill out our form and we will get back to you.